Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Diagnostics

Exact Sciences acquires liquid-biopsy start-up Thrive in $2.15 billion deal

by Ryan Cross
October 31, 2020 | A version of this story appeared in Volume 98, Issue 42

 

Exact Sciences, a diagnostics firm that sells the colon cancer test Cologuard, will acquire the liquid-biopsy start-up Thrive Earlier Detection for $1.7 billion, plus $450 million in potential milestone payments. Thrive launched in 2019 based on the work of three oncologists at Johns Hopkins University who had developed a blood test, CancerSEEK,that analyzes DNA and proteins in seemingly healthy people to spot early signs of cancer. The buyout comes just 1 month after the DNA sequencing giant Illumina announced that it would buy the liquid-biopsy start-up Grail for $8 billion.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.